Goodbye 2022—The Top 10 Biosimilars Stories of the Year

On this episode, we’re going to review the top stories and milestones to hit the biosimilar industry this year. From the launch of a generic lenalidomide, the FDA approval of a high-concentration adalimumab biosimilar, to the launch of the first ophthalmology biosimilar. We’re also going to be recommending our top 5 podcast episodes of the year so stick around to hear more about what 2022 has in store for biosimilars around the world.

Show notes

Top 10 stories of the year:

10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar

9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA

8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023

7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology

6. Report: Biosimilar Competition in Europe

5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options

• For the whole series, click here.

4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira

3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab

2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar

1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid

Top 5 podcast episodes of the year:

5. How Health Policy Can Impact Adoption for Adalimumab Biosimilars

4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar

3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market

1. What Will Year 1 Look Like for Adalimumab Biosimilars?